Truscreen GroupASX:TRU EBIT per Share is A$-0.00 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Truscreen Group ranks better than 60.41% on this metric.
Truscreen Group's EBIT per Share for the
six
months ended in Mar. 2026 was A$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 17.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 26.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 16.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Truscreen Group's EBIT per Share or its related term are showing as below:
ASX:TRU'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.2 Med: 17 Max: 43.3
Current: 17
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Truscreen Group was 43.30% per year. The lowest was -44.20% per year. And the median was 17.00% per year.
ASX:TRU's 3-Year EBIT Growth Rate is ranked better than 60.41% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.4
vs ASX:TRU: 17.00
Truscreen Group's EBIT for the
six
months ended in Mar. 2026 was A$0.00 Mil.
Truscreen Group (ASX:TRU) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Truscreen Group EBIT per Share Related Terms
Truscreen Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Truscreen Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a EBIT per Share of A$-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Truscreen Group and its competitors. According to the industry distribution chart, Truscreen Group ranks #272 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 39.6%.
Is Truscreen Group's EBIT per Share too high?
Truscreen Group's current EBIT per Share is A$-0.00. Based on the distribution chart, Truscreen Group ranks #272 out of 687 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Truscreen Group's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #272 out of 687 companies for EBIT per Share. This puts Truscreen Group in the upper half of its industry. The industry median EBIT per Share is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current EBIT per Share is A$-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 30% above its estimated fair value. The current EBIT per Share is A$-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current EBIT per Share is A$-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 